Clinical trials: Depressive
Depression, Alcoholism
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to…
- Conditions
- Depression, Alcoholism, Suicidal Behavior
- Trial name
- NCT00449007
- Testing
- fluoxetine, bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Efficacy Study of Korean Red Ginseng to Treat Depression
The purpose of this study is to determine whether Korean Red Ginseng are effective in the treatment of the residual symptoms of depression as an adjuvant treatment.
- Trial name
- NCT01496248
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Korea University
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder, Insomnia
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.
- Trial name
- NCT03771664
- Testing
- SAGE-217
- Where
- 28 sites in United States
- Volunteers
- 87 people
- Sponsor
- Biogen
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Depression
Measuring Quality of Decisions About Treatment of Depression
The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of depression.
- Trial name
- NCT01152307
- Testing
- DVD/Booklet: Coping with Symptoms of Depression
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- University of Massachusetts, Boston
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder, Alcohol Abuse
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will…
- Conditions
- Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT00452543
- Testing
- acamprosate, escitalopram, Medical management
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Depression
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
This study will determine the effectiveness of an antidepressant in preventing or reducing depressive symptoms in people with melanoma who are receiving Interleukin-2 (IL-2) treatment.
- Trial name
- NCT00352885
- Testing
- Escitalopram, IL-2
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Major Depressive Disorder
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in…
- Trial name
- NCT00876343
- Testing
- Aripiprazole (Fixed dose), Aripiprazole (Titrated dose)
- Where
- 8 sites in Japan
- Volunteers
- 586 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine.
- Trial name
- NCT00360126
- Testing
- lamotrigine
- Where
- 3 sites in Australia
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
- Trial name
- NCT01670279
- Testing
- Brexpiprazole
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been…
- Trial name
- NCT00429169
- Testing
- Paroxetine, Bupropion
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- New York State Psychiatric Institute
PostPartum Depression
The Effect of Exercise on Preventing PostPartum Depression
The purpose of this study is to examine the feasibility and efficacy of an exercise intervention for the prevention of postpartum depression.
- Trial name
- NCT00961402
- Testing
- Wellness Control, Exercise Intervention
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.